EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Prenatal and Early Childhood Exposure to Proton Pump Inhibitors and Antibiotics and the Risk of Childhood Cancer: A Nationwide Population-Based Cohort Study

Unnur Gudnadottir iD, Emma Fransson, Gustaf Ljungman, Anna Wikman, Erika Vlieghe, Lars Engstrand, Nele Brusselaers

Drug Safety · 2025

DOI: 10.1007/s40264-024-01500-x ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Drug Safety, 2025. Verfasst von Unnur Gudnadottir und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Tumour and Cell Biology (MTC), Centre for Translational Microbiome Research, Karolinska Institutet, Tomtebodavägen 16, So…. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Anti-Bacterial Agents, Prenatal Exposure Delayed Effects, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Vetenskapsrådet, Karolinska Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Our microbiome is established during infancy, a time important for later health and long-term effects. Proton pump inhibitors and antibiotics are regularly prescribed during pregnancy. Both drugs cause microbiome disturbance and have been associated with increased cancer risk in adults, but effects of these drugs on the growing foetus and infant remain understudied. AIM: The aim of this study is to study the association between prenatal and early life proton pump inhibitor and antibiotics exposure and the risk of childhood cancer. METHODS: This study is a retrospective population-based cohort design, using registry data on all births (n = 722,372) in Sweden between 2006 and 2016, according to the STROBE checklist. For women who had multiple children in the timeframe of the study, only the first child during the time period was included in the cohort. Exposure was defined as either ≥ 1 proton pump inhibitor or antibiotics prescription during pregnancy, or during the first 2 years of life. Outcome was defined as cancer at any time during the follow-up or cancer after the age of 2 years for early life exposure. Multivariable Cox proportional hazard models were used to calculate hazard ratios. RESULTS: In total, 1091 (0.2%) children were diagnosed with malignant cancer during the follow-up. Prenatal exposure to proton pump inhibitors and antibiotics were not associated with an increased risk of cancer. Regarding early life exposure, proton pump inhibitors were associated with an increased risk of cancer at age two or older (adjusted hazard ratio [aHR] 3.68, 95% confidence interval [CI] 2.24-6.06). CONCLUSIONS: We did not find evidence that prenatal proton pump inhibitors and antibiotics were associated with overall childhood cancer. However, proton pump inhibitors during early life were associated with an increased risk of childhood cancer, but indication on drug use was not available and confounding by indication may be present.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proton Pump InhibitorsAnti-Bacterial AgentsPrenatal Exposure Delayed EffectsNeoplasmsHumansFemalePregnancyRetrospective StudiesSwedenInfantMaleCohort StudiesChild, PreschoolAdultInfant, NewbornRegistriesRisk FactorsChild

Substanzen

Proton Pump InhibitorsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Microbiology, Tumour and Cell Biology (MTC), Centre for Translational Microbiome Research, Karolinska Institutet, Tomtebodavägen 16, Solna, 171 65, Stockholm, Sweden. unnur.gudnadottir@ki.se.
  • Department of Microbiology, Tumour and Cell Biology (MTC), Centre for Translational Microbiome Research, Karolinska Institutet, Tomtebodavägen 16, Solna, 171 65, Stockholm, Sweden.
  • Department of Women's and Children's health, Uppsala University, Sjukhusvägen 7, 753 09, Uppsala, Sweden.
  • Department of Family Medicine and Population Health, Global Health Institute, University of Antwerp, 2610, Antwerp, Belgium.
  • Department of Public Health and Primary Care, Ghent University, 9000, Ghent, Belgium.

ORCID-Profile: Unnur Gudnadottir

Förderung

  • Vetenskapsrådet
  • Karolinska Institute

Zitieren

APA

Gudnadottir, U., Fransson, E., Ljungman, G., Wikman, A., Vlieghe, E., Engstrand, L., & Brusselaers, N. (2025). Prenatal and Early Childhood Exposure to Proton Pump Inhibitors and Antibiotics and the Risk of Childhood Cancer: A Nationwide Population-Based Cohort Study. Drug Safety. https://doi.org/10.1007/s40264-024-01500-x

Vancouver

Gudnadottir U, Fransson E, Ljungman G, Wikman A, Vlieghe E, Engstrand L, et al. Prenatal and Early Childhood Exposure to Proton Pump Inhibitors and Antibiotics and the Risk of Childhood Cancer: A Nationwide Population-Based Cohort Study. Drug Safety. 2025. doi:10.1007/s40264-024-01500-x

BibTeX
@article{Gudnadottir2025,
  author = {Gudnadottir, Unnur and Fransson, Emma and Ljungman, Gustaf and Wikman, Anna and Vlieghe, Erika and Engstrand, Lars and Brusselaers, Nele},
  title = {Prenatal and Early Childhood Exposure to Proton Pump Inhibitors and Antibiotics and the Risk of Childhood Cancer: A Nationwide Population-Based Cohort Study},
  journal = {Drug Safety},
  year = {2025},
  doi = {10.1007/s40264-024-01500-x}
}
Kostenlos starten →